Related references
Note: Only part of the references are listed.ROS in cancer therapy: the bright side of the moon
Bruno Perillo et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
Glycogen synthase kinase-3 inhibition in glioblastoma multiforme cells induces apoptosis, cell cycle arrest and changing biomolecular structure
Eda Acikgoz et al.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY (2019)
Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets
Olivia G. Taylor et al.
FRONTIERS IN ONCOLOGY (2019)
Emerging functions of the EGFR in cancer
Sara Sigismund et al.
MOLECULAR ONCOLOGY (2018)
Inhibiting TRK Proteins in Clinical Cancer Therapy
Allison M. Lange et al.
CANCERS (2018)
Targeting mutant p53 for efficient cancer therapy
Vladimir J. N. Bykov et al.
NATURE REVIEWS CANCER (2018)
Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel
Angela Zacher et al.
BRAIN PATHOLOGY (2017)
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
Hua-fu Zhao et al.
MOLECULAR CANCER (2017)
Biological basis and clinical study of glycogen synthase kinase-3β-targeted therapy by drug repositioning for glioblastoma
Takuya Furuta et al.
ONCOTARGET (2017)
Targeting cellular pathways in glioblastoma multiforme
Joshua R. D. Pearson et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)
EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation
Yuho Hamaoka et al.
CELLULAR SIGNALLING (2016)
Migrating glioma cells express stem cell markers and give rise to new tumors upon xenografting
Sune Munthe et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma
Shaofang Wu et al.
MOLECULAR CANCER THERAPEUTICS (2016)
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Xiaoman Li et al.
ONCOTARGET (2016)
RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics
Florian J. Sulzmaier et al.
ONCOTARGET (2016)
MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma
Tian Tian et al.
ONCOTARGET (2016)
Targeting SOX2 as a Therapeutic Strategy in Glioblastoma
Laura Garros-Regulez et al.
FRONTIERS IN ONCOLOGY (2016)
Systemic Inhibition of CREB is Well-tolerated in vivo
Bingbing X. Li et al.
SCIENTIFIC REPORTS (2016)
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Paul Foster et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition
Monal Mehta et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma
Emily Padfield et al.
FRONTIERS IN ONCOLOGY (2015)
Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer
Hui Jun Lim et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Glycogen Synthase Kinase 3β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway
Yuri Chikano et al.
MOLECULAR CANCER THERAPEUTICS (2015)
The MAPK Pathway Across Different Malignancies: A New Perspective
Mauricio Burotto et al.
CANCER (2014)
Glucose-6-phosphatase Is a Key Metabolic Regulator of Glioblastoma Invasion
Sara Abbadi et al.
MOLECULAR CANCER RESEARCH (2014)
Inhibitors of NF-kappaB reverse cellular invasion and target gene upregulation in an experimental model of aggressive oral squamous cell carcinoma
Jeff Johnson et al.
ORAL ONCOLOGY (2014)
FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway
Li Zhang et al.
TUMOR BIOLOGY (2014)
Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation
P. Daniel et al.
ONCOGENESIS (2014)
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Howard A. Burris
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Glycogen synthase kinase 3 inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling
Ilya V. Pyko et al.
CARCINOGENESIS (2013)
The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Beatrice Gini et al.
CLINICAL CANCER RESEARCH (2013)
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Glioma Spheroids Obtained via Ultrasonic Aspiration Are Viable and Express Stem Cell Markers: A New Tissue Resource for Glioma Research
Stine Skov Jensen et al.
NEUROSURGERY (2013)
Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding
Arshawn Sami et al.
TUMOR BIOLOGY (2013)
Deregulated Signaling Pathways in Glioblastoma Multiforme: Molecular Mechanisms and Therapeutic Targets
Hua Mao et al.
CANCER INVESTIGATION (2012)
The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Craig P. Carden et al.
MOLECULAR CANCER THERAPEUTICS (2012)
cAMP response element-binding protein promotes gliomagenesis by modulating the expression of oncogenic microRNA-23a
Xiaochao Tan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Therapeutic Strategies to Target Multiple Kinases in Glioblastoma
Sith Sathornsumetee
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2011)
TGFβ Activates Mitogen- and Stress-activated Protein Kinase-1 (MSK1) to Attenuate Cell Death
Lars P. van der Heide et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Genetic and Epigenetic Modifications of Sox2 Contribute to the Invasive Phenotype of Malignant Gliomas
Marta M. Alonso et al.
PLOS ONE (2011)
AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth
Kyla M. Grimshaw et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
GSK3β Regulates Differentiation and Growth Arrest in Glioblastoma
Serdar Korur et al.
PLOS ONE (2009)
SOX2 Silencing in Glioblastoma Tumor-Initiating Cells Causes Stop of Proliferation and Loss of Tumorigenicity
Rosaria Maria Rita Gangemi et al.
STEM CELLS (2009)
Share Paper
